Amgen v Sanofi and Regeneron: Broad antibody patents held invalid for lack of enablement in US Lack of enablement: A conclusion of lack of enablement means that the disclosure provided in the patent specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full… Read more »